C:\Documents and Settings\EBernhardt\My Documents



chain nodes :
18 19 34 35 36 37 38 39 40 41 42
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 24 25 26 27 28 29 30 31 32 33
chain bonds :
7-13 12-41 12-42 14-37 14-38 15-35 15-36 16-18 17-39 17-40 18-19 32-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16 16-17
24-25 24-29 25-26 26-27 27-28 27-30 28-29 28-33 30-31 31-32 32-33
exact/norm bonds :
4-7 5-9 7-8 7-13 8-9 12-13 12-17 12-41 12-42 13-14 14-15 14-37 14-38 15-16
15-35 15-36 16-17 16-18 17-39 17-40 18-19 27-30 28-33 30-31 31-32 32-33 32-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 12 :

G1:C,O,S,N

G2:C,N

G3:C,O,N

G4:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:Atom 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 24:Atom 25:Atom 26:CLASS 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS

```
=> d que stat
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l5
SAMPLE SEARCH INITIATED 18:03:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      302 TO ITERATE

100.0% PROCESSED      302 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          4998 TO     7082
PROJECTED ANSWERS:                0 TO        0

L6            0 SEA SSS SAM L5

=>
Uploading C:\Documents and Settings\EBernhardt\My
Documents\Stnexp\Queries\10660908-3.str
```










```
chain nodes :
18  19  34  35  36  37  38  39  40  41  42
ring nodes :
1  2  3  4  5  6  7  8  9  12  13  14  15  16  17  24  25  26  27  28  29  30  31
32  33
chain bonds :
7-13  12-41  12-42  14-37  14-38  15-35  15-36  16-18  17-39  17-40  18-19  32-34
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-9  7-8  8-9  12-13  12-17  13-14  14-15  15-16
 16-17  24-25  24-29  25-26  26-27  27-28  27-30  28-29  28-33  30-31  31-32  32-33

exact/norm bonds :
4-7  5-9  7-8  7-13  8-9  12-13  12-17  12-41  12-42  13-14  14-15  14-37  14-38
15-16  15-35  15-36  16-17  16-18  17-39  17-40  18-19  27-30  28-33  30-31  31-32
32-33  32-34
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  24-25  24-29  25-26  26-27  27-28  28-29
isolated ring systems :
containing 12 :
```

G1:C,O,S,N

G2:C,N

G3:C,O,N

G4:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 24:Atom 25:Atom
26:CLASS 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS
35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS

L7 STRUCTURE UPLOADED

=> s l7
SAMPLE SEARCH INITIATED 18:05:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 138 TO ITERATE

100.0% PROCESSED 138 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2056 TO 3464
PROJECTED ANSWERS: 11 TO 389

L8 10 SEA SSS SAM L7

=> s l7 sss full
FULL SEARCH INITIATED 18:05:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2961 TO ITERATE

100.0% PROCESSED 2961 ITERATIONS 259 ANSWERS
SEARCH TIME: 00.00.01

L9 259 SEA SSS FUL L7

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 165.63 533.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -29.20

FILE 'CAPLUS' ENTERED AT 18:05:30 ON 18 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Sep 2005 VOL 143 ISS 13
FILE LAST UPDATED: 16 Sep 2005 (20050916/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l9
L10 8 L9

=> d l10 1-8 bib abs fhitstr

L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:638875 CAPLUS
DN 143:153404
TI Preparation of N-substituted piperidine and piperazine derivatives dopamine D2 and serotonin 2A receptor antagonists
IN Cho, Stephen Sung Yong; Gregory, Tracy Fay; Guzzo, Peter Robert; Howard, Harry Ralph, Jr.; Nikam, Sham Shridhar; Surman, Matthew David; Walters, Michael Anthony
PA Warner-Lambert Company Llc., USA
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066165	A1	20050721	WO 2004-IB4239	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-533761P	P	20031231		

GI



I



II

AB This invention relates to N-substituted piperidine and piperazine derivs. (shown as I; variables defined below; e.g. [5-[2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2,3-dihydroindol-1-yl](4-fluorophenyl)methanone (shown as II)), pharmaceutical compns. contg. them and their use in the treatment of central nervous system and other disorders. Although the methods of prepn. are not claimed, example prepns. and/or characterization data for .apprx.160 I are included. For example, II was prepd. in 98 % yield by coupling 3-[4-[2-(3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)ethyl]piperazin-1-yl]benzo[d]isothiazole with 4-fluorobenzoyl chloride; the benzo[d]isothiazole reactant was prepd. in 79 % yield by redn. of 5-[2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in 96 % yield from 3-(piperazin-1-yl)benzo[d]isothiazole and 5-(2-chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in 45 % yield by redn. of 5-(2-chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in >96 % yield from chloroacetyl chloride and 3,3-dimethyl-1,3-dihydroindol-2-one. For I: M = E-R9, L-T-R9, T-D-R9; U is S, O, SO, SO2, CH2 or NR3; V is N or C; Z is N or C; A is -(CH2)mO-, -(CH2)mNR4-, or -(CH2)mC(R5R6)-, wherein R5 and R6 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms, (C1-C4) alkoxy (un)substituted with 1-3 F atoms, hydroxy, and aminoalkyl; or R5 and R6 together form a carbonyl, and wherein m = 1-4. R1 and R2 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms, (C1-4) alkoxy (un)substituted with 1-3 F atoms, halogen, nitro, cyano, amino, (C1-C4) alkylamino and di(C1-C4) alkylamino; R3 and R4 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms and (C1-C4) alkoxy (un)substituted with 1-3 F atoms; or, when U is NR3, one of R1 and R2 can form, together with the C to which it is attached, and together with R3 and the N to which it is attached, a heterocyclic ring contg. 4-7 ring members of which 1-3 ring members can be N, O and S, and of which the remaining ring members are C, with the proviso that when R3 forms a ring with one of R1 and R2, the other of R1 and R2 is absent. X is -[C(R11)(R12)]o-, wherein R11 and R12 = H and (C1-C4) alkyl (un)substituted with 1-3 F atoms, and wherein o = 0-3, with the proviso that when W is absent, o .gtoreq.2; W is -[C(R13)(R14)]p-, wherein R13 and R14 = H and (C1-C4) alkyl (un)substituted with 1-3 F atoms, and wherein p = 0-4, with the proviso that when X is absent, p .gtoreq.2; R7 and R8 = halo, R1 and -OR1; or R7, when attached to a C adjacent to one of the C atoms shared by both the Ph

ring to which R7 is attached and the ring contg. W, N and X, forms, together with a C atom of X or a C atom of W, a satd. carbocyclic ring contg. 3-6 C atoms. R9 = Ph, phenoxy, benzyloxy, and phenylamino, wherein the Ph moieties are (un)substituted with 1-3 halo, (C1-C3) alkyl (un)substituted with 1-3 F atoms, (C1-C3) alkoxy (un)substituted with 1-3 F atoms, nitro, cyano, amino, and (C1-C3) alkylamino; or R9 is a pyrrolidine, piperidine or morpholine ring wherein the point of attachment to D, T or E is the ring N, and wherein said pyrrolidine, piperidine or morpholine ring can be (ùn)substituted with 1 or 2 Me, amino, (C1-04) alkylamino, and di(C1-C4) alkylamino; or R9 is a furan, thiophene, or pyrazole ring (un)substituted with 1-2 (C1-C4) alkyl groups; or R9 is (C1-C6) straight or branched alkyl or (C3-C6) cycloalkyl, wherein said straight, branched and cyclic alkyl moieties are be (un)substituted with 1-3 halo atoms or (C1-C4) alkoxy (un)substituted with 1-3 F atoms; or R9 is halogen, nitro, cyano, amino, (C1-C4) alkylamino, di(C1-C4) alkylamino or OR1, wherein the alkyl moieties of (C1-C4) alkylamino and di(C1-C4) alkylamino are (un)substituted with an amino, (C1-C4) alkylamino, or di(C1-C4) alkylamino group; E is -C(O)-, -S(O)- or -SO2-; T is -C(O)- or -CO2-; L is -(CH2)n wherein n = 0-3; D is -(CHR10)q-, wherein q = 1-3, or NR10; R10 is H or straight or branched (C1-C3) alkyl.

IT **676116-01-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-substituted piperidine and piperazine derivs. dopamine D2 and serotonin 2A receptor antagonists)

RN 676116-01-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:287843 CAPLUS

DN 140:321381

TI Preparation of heterocyclic substituted piperazines for the treatment of schizophrenia

IN Davis, Jamie Marie; Gregory, Tracy Fay; Walters, Michael Anthony

PA Warner-Lambert Company Llc, USA

SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029048	A1	20040408	WO 2003-IB4113	20030918

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2500115	AA	20040408	CA 2003-2500115	20030918
	EP 1546145	A1	20050629	EP 2003-798314	20030918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014796	A	20050726	BR 2003-14796	20030918
	US 2004067960	A1	20040408	US 2003-672949	20030926
PRAI	US 2002-413839P	P	20020926		
	WO 2003-IB4113	W	20030918		

OS MARPAT 140:321381

GI



I

AB The title compds. [I; Ar = 1,2-benzisothiazoyl, 1,2-benzisothiazoyl -1-oxide, naphthyl, pyridyl, etc.; with the proviso that Ar can not be attached to the piperazine ring via a Ph ring of Ar; Y = N, CH; A = (CH2)nCH2 (wherein n = 1-4, one of the CH2 groups that is not adjacent to the piperazine nitrogen can be replaced by an oxygen atom); R2, R3 = H, alkyl, fluoroalkyl, alkoxy, etc.; Q = (un)satd. (un)substituted 5-7 membered monocyclic heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S], useful in the treatment of central nervous system disorders, were prepd. Thus, reacting 3-methylbut-2-enoic acid (2-{2-[4-(1,2-benzisothiazol-3-yl)-piperazin-1-yl]ethyl}phenyl)amide (prepn. given) with AlCl3 in C6H5Cl afforded 8-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one which showed Ki of .ltoreq. 1 .mu.M against dopamine D2 receptor binding, and Ki of .ltoreq. 1 .mu.M against 5-HT2A receptor binding. The pharmaceutical compn. comprising the compd. I is claimed.

IT **677708-34-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-34-8 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:267327 CAPLUS
DN 140:287412
TI Preparation of piperazines as dopamine D2 and serotonin 5HT2A receptors inhibitors for the treatment of central nervous system disorders, in particular schizophrenia
IN Andreana, Tonja Lynn; Cho, Stephen Sung Yong; Graham, James Michael; Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Kornberg, Brian Edward; Nikam, Sham Shridhar; Pflum, Derek Andrew
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026864	A1	20040401	WO 2003-IB3902	20030905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499326	AA	20040401	CA 2003-2499326	20030905
	EP 1546143	A1	20050629	EP 2003-797433	20030905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014393	A	20050719	BR 2003-14393	20030905
	US 2004138230	A1	20040715	US 2003-660908	20030912

Apps

PRAI US 2002-411475P P 20020917
US 2002-416355P P 20021004
WO 2003-IB3902 W 20030905
OS MARPAT 140:287412
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X =S, O, SO, SO2, CH2, NH and derivs.; Y, Z = independently N or CH; A = (CH2)mCH2, (CH2)mO, (CH2)mNR9, (CH2)mC(R7R8); R7, R8 = independently (un)substituted alkyl, alkoxy, or CR7R8 = carbonyl; m = 1-4; R4, R5 = independently H, (un)substituted alkyl, alkoxy, or when X = NR6 and derivs., CR4R5R6N = 4-7 membered heterocyclyl ring, with the proviso that when R9R4 or R9R5 = a ring, the other of R4 and R5 is absent; R9 = H, (un)substituted alkyl, alkoxy; R6 = H, (un)substituted alkyl, alkoxy; R1 = H, (un)substituted alkyl; R2, R3 = independently H, halo, hetero/aryl, (un)substituted aryl/heteroarylalkyl, alkoxy, etc.; V, W = independently CH2 and derivs. or CH and derivs.; and their pharmaceutically acceptable salts] were prepd. s dopamine D2 and serotonin 5HT2A receptors inhibitors for treating central nervous system disorders, in particular schizophrenia (no data). For example, II.bul.MeSO3H was prepd. by acylation of 3-chloro-2-methylaniline with 3,3-diethylacryloyl chloride, one-pot Friedel-Craft alkylation with chloroacetyl chloride and cyclization in the presence of AlCl3 to chloroacetylquinoline intermediate, redn. to chloroethylquinoline III, alkylation of 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride with III, followed by salt formation of II with methanesulfonic acid. II acted as dopamine D2 and serotonin 5HT2A receptors inhibitors with a Ki value of 0.9 nm and 1 nM, resp. Thus, I and their formulations are useful for treating central nervous system disorders, in particular schizophrenia and depression.

IT **676117-35-4P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 676117-35-4 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:732486 CAPLUS
DN 138:331185
TI New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives with atypical antipsychotic binding profile
AU Orjales, Aurelio; Mosquera, Ramon; Toledo, Antonio; Pumar, Carmen; Labeaga, Luis; Innerarity, Ana
CS Research Department, FAES FARMA, S.A., Leioa, E-48940, Spain
SO European Journal of Medicinal Chemistry (2002), 37(9), 721-730
CODEN: EJMCA5; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 138:331185
AB New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivs. were synthesized and their 5-HT1A, 5-HT2A and D2 receptor binding affinities evaluated. The compds. displayed high affinity for the 5-HT2A receptor combined with moderate to low 5-HT1A and D2 affinities. Two of them have been selected for further pharmacol. studies to be evaluated as potential atypical antipsychotics.
IT **516509-59-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzisothiazolyl and benzisoxazolylpiperazine derivs. with atypical antipsychotic binding profile)
RN 516509-59-4 CAPLUS
CN 2(1H)-Quinolinone, 1-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:10184 CAPLUS
DN 130:38398

TI Quinolin-2(1H)-one derivatives as serotonin antagonists
IN McCort, Gary; Hoornaert, Christian; Duclos, Olivier; Cadilhac, Caroline; Guilpain, Eric
PA Synthelabo S. A., Fr.
SO Fr. Demande, 38 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2761067	A1	19980925	FR 1997-3388	19970320
FR 2761067	B1	19990423		
PRAI FR 1997-3388		19970320		

OS MARPAT 130:38398
GI



I



HCl

II

AB Quinolinones I [R1, R2 = H, halogen, NH2, OH, NO2, CN, alkyl, alkoxy, CF3, OCF3, CO2R5, carbamoyl, SR5, SO2R5, NHNCOR5, NHSO2R5, NR52 (R5 = alkyl); R3 = H, (un)substituted alkyl; R4 = H, halogen, OH, NO2, CN, alkyl, alkoxy, CF3, CONH2, NHSO2Me; m = 2-4; Z = N, CH; A = O, NH, S, NR5] were prepd. for use as serotonin antagonists (no data). Thus, the quinolinone II was obtained from the chloroethylquinolinone and the piperidinylisoxazole fragments.
IT **216674-97-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of quinolinone derivs. as serotonin antagonists)
RN 216674-97-4 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:682542 CAPLUS
DN 123:83356
TI Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect
IN Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro
PA Meiji Seika K. K., Japan
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418197	A1	19940818	WO 1994-JP159	19940203
	W: CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 635506	A1	19950125	EP 1994-905841	19940203
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1103534	A	19950607	CN 1994-190042	19940203
	CN 1050604	B	20000322		
	US 5599815	A	19970204	US 1994-318857	19941220
PRAI	JP 1993-17505	A	19930204		
	WO 1994-JP1	A	19940104		
	WO 1994-JP159	W	19940203		

OS MARPAT 123:83356
GI



I



AB Compds. represented by general formula [I; n = 2-4; W = heterocyclyl, e.g., Q - Q2; m = 0-2; A = CH2, CH, N, NH; B = CH2, CH, N, NH, S; provided that both A and B .noteq. N or NH; X = CH, N, S, bond; Y = CH, N; R1 = H, halo, lower (halo)alkyl, (un)substituted Ph, OH, NO2, lower alkoxy, NH2, cyano; R2, R3 = H, halo, lower (halo)alkyl or alkoxy, NH2, cyano, provided that when X = bond, R2 is not present; or R2R3 = (CH2)p (wherein p = 3-5)] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and K2CO3 0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title compd. I (n = 4, W = 2-oxo-1,2-dihydro-1-quinolinyl). II (n = 4, W = 9-carbazolyl) and II (n = 3, W = 2-oxo-1,2-dihydro-1-quinolinyl) showed ED50 of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05 mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).

IT **165109-31-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [N-(heterocyclylalkyl)piperazinyl]benzisothiazole derivs. as antipsychotics)

RN 165109-31-9 CAPLUS

CN 2(1H)-Quinolinone, 1-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:657604 CAPLUS
DN 123:55870
TI Preparation of indazole derivatives as antipsychotics
IN Sasaki, Toshiro; Nakatani, Juko; Hiranuma, Toyoichi; Kashima, Hiroko; Fukuda, Yoshimasa
PA Meiji Seika Co, Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07033744	A2	19950203	JP 1993-204612	19930727
PRAI	JP 1993-204612		19930727		

OS MARPAT 123:55870
GI



I



II

AB The title compds. I [n = 2 - 6; V = H, halo; R1 = H, alkyl, etc.; W = heterocycle (further details on said heterocycle are given)] are prepd. Indazole deriv. II (prepn. given) showed ED50 of 0.50 mg/Kg i.p. against methamphetamine-induced activities in mice, vs. ED50 of 0.16 mg/Kg i.p. shown by haloperidol. In a test for catalepsy-causing activity in mice, II showed ED50 of 18 mg/Kg i.p., vs. ED50 of 1.3 mg/Kg i.p. shown by haloperidol.

IT **164519-46-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indazole derivs. as antipsychotics)

RN 164519-46-4 CAPLUS

CN 6(5H)-Phenanthridinone, 5-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:492295 CAPLUS

DN 115:92295

TI Preparation of heteroarylpiperazines as antipsychotic agents

IN Howard, Harry R.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409435	A1	19910123	EP 1990-307166	19900629
	EP 409435	B1	19941026		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9100863	A1	19910124	WO 1989-US2954	19890707
	W: FI, HU, NO, RO, SU, US				
	ES 2062374	T3	19941216	ES 1990-307166	19900629
	JP 03044388	A2	19910226	JP 1990-176120	19900703
	JP 07017633	B4	19950301		
	CA 2020611	AA	19910108	CA 1990-2020611	19900706
	US 5350747	A	19940927	US 1992-836019	19920220
PRAI	WO 1989-US2954	A	19890707		

OS MARPAT 115:92295
GI



I

II



III



IV

AB The title compds. [I; W1 = CR2R3; W2 = CR4R5; W3 = CR6R7; 1 of W1-W3 may be absent; R1 = (substituted) benzisoxazolyl, benzisothiazolyl, benzopyrazolyl; R2-R7 = H, alkyl, 2 of them may form alkylene, alkenylene; X1 = H, halo, C1-4 alkyl, alkoxy, NO2, cyano, etc.; Y1 = H, C1-4 alkyl, (substituted) Ph, etc.; X1Y1 = heterocyclyl; Z = C1-6 alkylene], useful as antipsychotic agents (no data), were prepd. A mixt. of piperazine deriv. II, quinolinone III (prepn. given), Na2CO3, and KI in MIBK was heated at 90.degree. under N to give 13% title compd. IV, sepd. as HCl.1/2 H2O. Also prepd. were 17 addnl. I and numerous intermediates.

IT **133999-10-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antipsychotic agent)
RN 133999-10-7 CAPLUS
CN 2(1H)-Quinolinone, 7-chloro-3,4-dihydro-6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



=> d l10 4-8 bib abs hitstr

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:732486 CAPLUS
DN 138:331185
TI New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives with atypical antipsychotic binding profile
AU Orjales, Aurelio; Mosquera, Ramon; Toledo, Antonio; Pumar, Carmen; Labeaga, Luis; Innerarity, Ana
CS Research Department, FAES FARMA, S.A., Leioa, E-48940, Spain
SO European Journal of Medicinal Chemistry (2002), 37(9), 721-730
CODEN: EJMCA5; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 138:331185
AB New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivs. were synthesized and their 5-HT1A, 5-HT2A and D2 receptor binding affinities evaluated. The compds. displayed high affinity for the 5-HT2A receptor combined with moderate to low 5-HT1A and D2 affinities. Two of them have been selected for further pharmacol. studies to be evaluated as potential atypical antipsychotics.
IT **516509-59-4P 516509-64-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzisothiazolyl and benzisoxazolylpiperazine derivs. with atypical antipsychotic binding profile)
RN 516509-59-4 CAPLUS
CN 2(1H)-Quinolinone, 1-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 516509-64-1 CAPLUS
CN 2,4(1H,3H)-Quinolinedione, 1-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:10184 CAPLUS
DN 130:38398
TI Quinolin-2(1H)-one derivatives as serotonin antagonists
IN McCort, Gary; Hoornaert, Christian; Duclos, Olivier; Cadilhac, Caroline; Guilpain, Eric
PA Synthelabo S. A., Fr.
SO Fr. Demande, 38 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI FR 2761067 A1 19980925 FR 1997-3388 19970320
FR 2761067 B1 19990423
PRAI FR 1997-3388 19970320
OS MARPAT 130:38398
GI



I



HCl

II

AB Quinolinones I [R1, R2 = H, halogen, NH2, OH, NO2, CN, alkyl, alkoxy, CF3, OCF3, CO2R5, carbamoyl, SR5, SO2R5, NHNCOR5, NHSO2R5, NR52 (R5 = alkyl); R3 = H, (un)substituted alkyl; R4 = H, halogen, OH, NO2, CN, alkyl, alkoxy, CF3, CONH2, NHSO2Me; m = 2-4; Z = N, CH; A = O, NH, S, NR5] were prepd. for use as serotonin antagonists (no data). Thus, the quinolinone II was obtained from the chloroethylquinolinone and the piperidinylisoxazole fragments.

IT **216674-97-4P 216675-04-6P 216675-07-9P**
216675-23-9P 216675-46-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of quinolinone derivs. as serotonin antagonists)

RN 216674-97-4 CAPLUS

CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 216675-04-6 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1-methyl-1H-indazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 216675-07-9 CAPLUS
CN 1(2H)-Quinolineacetamide, 7-fluoro-4-[2-[4-(6-fluoro-1-methyl-1H-indazol-3-yl)-1-piperazinyl]ethyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 216675-23-9 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 216675-46-6 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



IT **216674-09-8P 216674-18-9P 216674-23-6P**
216674-30-5P 216674-36-1P 216674-43-0P
216674-49-6P 216674-53-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolinone derivs. as serotonin antagonists)
RN 216674-09-8 CAPLUS
CN 2(1H)-Quinolinone, 4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-18-9 CAPLUS
CN 2(1H)-Quinolinone, 4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-23-6 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-methoxy-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-30-5 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-36-1 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-43-0 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1-methyl-1H-indazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-49-6 CAPLUS
CN 1(2H)-Quinolineacetamide, 7-fluoro-4-[2-[4-(6-fluoro-1-methyl-1H-indazol-3-yl)-1-piperazinyl]ethyl]-2-oxo-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 216674-53-2 CAPLUS
CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:682542 CAPLUS
DN 123:83356
TI Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect
IN Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro
PA Meiji Seika K. K., Japan
SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418197	A1	19940818	WO 1994-JP159	19940203
	W: CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 635506	A1	19950125	EP 1994-905841	19940203
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1103534	A	19950607	CN 1994-190042	19940203
	CN 1050604	B	20000322		
	US 5599815	A	19970204	US 1994-318857	19941220
PRAI	JP 1993-17505	A	19930204		
	WO 1994-JP1	A	19940104		
	WO 1994-JP159	W	19940203		

OS MARPAT 123:83356
GI



I



AB Compds. represented by general formula [I; n = 2-4; W = heterocyclyl, e.g., Q - Q2; m = 0-2; A = CH2, CH, N, NH; B = CH2, CH, N, NH, S; provided that both A and B .noteq. N or NH; X = CH, N, S, bond; Y = CH, N; R1 = H, halo, lower (halo)alkyl, (un)substituted Ph, OH, NO2, lower alkoxy, NH2, cyano; R2, R3 = H, halo, lower (halo)alkyl or alkoxy, NH2, cyano, provided that when X = bond, R2 is not present; or R2R3 = (CH2)p (wherein p = 3-5)] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and K2CO3 0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title

compd. I (n = 4, W = 2-oxo-1,2-dihydro-1-quinolinyl). II (n = 4, W = 9-carbazolyl) and II (n = 3, W = 2-oxo-1,2-dihydro-1-quinolinyl) showed ED50 of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05 mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).

IT **165109-31-9P 165109-35-3P 165109-39-7P 165109-40-0P 165109-54-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [N-(heterocyclylalkyl)piperazinyl]benzisothiazole derivs. as antipsychotics)

RN 165109-31-9 CAPLUS
CN 2(1H)-Quinolinone, 1-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 165109-35-3 CAPLUS
CN 2(1H)-Quinolinone, 1-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 165109-39-7 CAPLUS
CN 6(5H)-Phenanthridinone, 5-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 165109-40-0 CAPLUS
CN Phenanthridine, 6-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 165109-54-6 CAPLUS
CN 2(1H)-Quinolinone, 1-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:657604 CAPLUS
DN 123:55870
TI Preparation of indazole derivatives as antipsychotics
IN Sasaki, Toshiro; Nakatani, Juko; Hiranuma, Toyoichi; Kashima, Hiroko; Fukuda, Yoshimasa
PA Meiji Seika Co, Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07033744	A2	19950203	JP 1993-204612	19930727
PRAI	JP 1993-204612		19930727		

OS MARPAT 123:55870
GI



I



II

AB The title compds. I [n = 2 - 6; V = H, halo; R1 = H, alkyl, etc.; W = heterocycle (further details on said heterocycle are given)] are prepd. Indazole deriv. II (prepn. given) showed ED50 of 0.50 mg/Kg i.p. against methamphetamine-induced activities in mice, vs. ED50 of 0.16 mg/Kg i.p. shown by haloperidol. In a test for catalepsy-causing activity in mice, II showed ED50 of 18 mg/Kg i.p., vs. ED50 of 1.3 mg/Kg i.p. shown by haloperidol.

IT **164519-46-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indazole derivs. as antipsychotics)

RN 164519-46-4 CAPLUS

CN 6(5H)-Phenanthridinone, 5-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butyl]-(9CI) (CA INDEX NAME)



IT **164519-94-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(prepn. of indazole derivs. as antipsychotics)
RN 164519-94-2 CAPLUS
CN 1H-Indazole, 1-[(4-methylphenyl)sulfonyl]-3-[4-[4-(6-oxo-5(6H)-phenanthridinyl)butyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:492295 CAPLUS
DN 115:92295
TI Preparation of heteroarylpiperazines as antipsychotic agents
IN Howard, Harry R.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409435	A1	19910123	EP 1990-307166	19900629
	EP 409435	B1	19941026		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9100863	A1	19910124	WO 1989-US2954	19890707
	W: FI, HU, NO, RO, SU, US				
	ES 2062374	T3	19941216	ES 1990-307166	19900629
	JP 03044388	A2	19910226	JP 1990-176120	19900703
	JP 07017633	B4	19950301		
	CA 2020611	AA	19910108	CA 1990-2020611	19900706
	US 5350747	A	19940927	US 1992-836019	19920220
PRAI	WO 1989-US2954	A	19890707		

OS MARPAT 115:92295
GI



I



II



III



IV

AB The title compds. [I; W1 = CR2R3; W2 = CR4R5; W3 = CR6R7; 1 of W1-W3 may be absent; R1 = (substituted) benzisoxazolyl, benzisothiazolyl, benzopyrazolyl; R2-R7 = H, alkyl, 2 of them may form alkylene, alkenylene; X1 = H, halo, C1-4 alkyl, alkoxy, NO2, cyano, etc.; Y1 = H, C1-4 alkyl, (substituted) Ph, etc.; X1Y1 = heterocyclyl; Z = C1-6 alkylene], useful as antipsychotic agents (no data), were prepd. A mixt. of piperazine deriv. II, quinolinone III (prepn. given), Na2CO3, and KI in MIBK was heated at 90.degree. under N to give 13% title compd. IV, sepd. as HCl.1/2 H2O. Also prepd. were 17 addnl. I and numerous intermediates.

IT **133999-10-7P 134017-19-9P 134017-20-2P**
134017-21-3P 134017-22-4P 134017-23-5P
134017-24-6P 134017-25-7P 134017-26-8P
134017-27-9P 134017-28-0P 134017-29-1P
134017-30-4P 134017-31-5P 134017-32-6P
135357-15-2P 135357-16-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antipsychotic agent)

RN 133999-10-7 CAPLUS

CN 2(1H)-Quinolinone, 7-chloro-3,4-dihydro-6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-19-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134017-20-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-21-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 134017-22-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 134017-23-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-7-methyl- (9CI) (CA INDEX NAME)



RN 134017-24-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-25-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-26-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,7-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-27-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-

3,4-dihydro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-28-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3-trimethyl- (9CI) (CA INDEX NAME)



RN 134017-29-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,7-trimethyl- (9CI) (CA INDEX NAME)



RN 134017-30-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-31-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-32-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 135357-15-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 135357-16-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```
=> file caold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        67.82     601.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -9.49     -38.69

FILE 'CAOLD' ENTERED AT 18:10:31 ON 18 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l9
L11           0 L9

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         1.29     602.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00     -38.69
```

FILE 'CAPLUS' ENTERED AT 18:12:10 ON 18 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Sep 2005 VOL 143 ISS 13
FILE LAST UPDATED: 16 Sep 2005 (20050916/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s US2003-660908/APPS
1 US2003-660908/AP
0 US2003-660908/PRN
L12 1 US2003-660908/APPS
(US2003-660908/AP,PRN)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.68	607.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-38.69

FILE 'REGISTRY' ENTERED AT 18:13:36 ON 18 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2005 HIGHEST RN 863378-74-9
DICTIONARY FILE UPDATES: 16 SEP 2005 HIGHEST RN 863378-74-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> tra l12 RN
L13          TRANSFER L12 1- RN :     350 TERMS
L14         350 L13

=> s l14 and piperazine/cn
             1 PIPERAZINE/CN
L15          1 L14 AND PIPERAZINE/CN

=> d scan l14

L14  350 ANSWERS   REGISTRY  COPYRIGHT 2005 ACS on STN
IN   Glycine, N-[3-[[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-
     piperazinyl]propyl]phenyl]amino]-3-oxopropyl]-N-methyl-, ethyl ester (9CI)
MF   C28 H37 N5 O3 S
```

PAGE 1-A



PAGE 1-B

—OEt

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L14  350 ANSWERS   REGISTRY  COPYRIGHT 2005 ACS on STN
IN   1,4,7-Trioxaspiro[4.4]nonane-9-carboxamide, N-[4-[2-[4-(1,2-benzisothiazol-
```

3-yl)-1-piperazinyl]ethyl]-2-methylphenyl]- (9CI)
MF C27 H32 N4 O4 S

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(7-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI)
MF C24 H25 F N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2,2-dimethylpropyl)-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C30 H40 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl- (9CI)
MF C30 H36 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-methylpropyl)- (9CI)
MF C27 H34 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-4-methyl- (9CI)
MF C25 H30 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(methoxymethyl)-3,3-dimethyl- (9CI)
MF C26 H32 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo-N-phenyl- (9CI)
MF C32 H35 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H,5H-Benzo[ij]quinolizin-5-one, 9-(2-chloroethyl)-2,3,6,7-tetrahydro-7,7-dimethyl- (9CI)
MF C16 H20 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-propyl- (9CI)
MF C25 H28 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(3-chloropropyl)-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C15 H20 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 1-acetyl-6-(3-chloropropyl)-1,2,3,4-tetrahydro-3,3-dimethyl- (9CI)
MF C16 H22 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-1,4,4-trimethyl- (9CI)
MF C26 H31 F N4 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-3-methyl- (9CI)
MF C24 H29 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI)
MF C24 H28 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (4S)- (9CI)

MF C24 H26 F N3 O S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisoxazole, 6-methyl-3-(1-piperazinyl)- (9CI)
MF C12 H15 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisothiazole, 5-methoxy-3-(1-piperazinyl)- (9CI)
MF C12 H15 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI)
MF C26 H32 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C25 H29 Cl N4 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI)
MF C24 H29 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(chloroacetyl)-3,4-dihydro-3,4-dimethyl- (9CI)
MF C13 H14 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4-dimethyl- (9CI)
MF C24 H28 N4 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisothiazole, 3-(1-piperazinyl)-, hydrochloride (9CI)
MF C11 H13 N3 S . x Cl H



●x HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(2-chloroethyl)-3,4-dihydro-4,4-dimethyl- (9CI)
MF C13 H16 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Butenamide, 3-methyl-N-(2-methylphenyl)- (9CI)
MF C12 H15 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisoxazole, 6-fluoro-3-(4-piperidinyl)- (9CI)
MF C12 H13 F N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Indazole, 3-chloro- (6CI, 8CI, 9CI)
MF C7 H5 Cl N2

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Cyclohexanecarboxylic acid, 2-oxo-, ethyl ester (6CI, 7CI, 8CI, 9CI)
MF C9 H14 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Butanoic acid, 4,4,4-trifluoro-3-oxo-, ethyl ester (9CI)
MF C6 H7 F3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4-trimethyl- (9CI)
MF C25 H30 N4 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4H-Pyrrolo[3,4-c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,5-tetrahydro-2-methyl- (9CI)
MF C26 H29 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4,7-Trioxaspiro[4.4]nonane-9-carboxylic acid, ethyl ester (9CI)
MF C9 H14 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(5-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI)
MF C24 H25 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-ethylbutyl)-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C31 H42 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-2-oxo-, ethyl ester (9CI)
MF C28 H32 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI)
MF C26 H29 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-oxo-2-phenylethyl)- (9CI)
MF C31 H32 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-3,3-dimethyl- (9CI)
MF C30 H38 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo- (9CI)
MF C25 H29 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H,5H-Benzo[ij]quinolizin-5-one, 2,3,6,7-tetrahydro-7,7-dimethyl- (9CI)
MF C14 H17 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro- (9CI)
MF C25 H26 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C26 H32 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-3,3-dimethyl- (9CI)
MF C27 H34 N4 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 7-fluoro-3,4-dihydro-4,4-dimethyl- (9CI)
MF C11 H12 F N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(3-chloropropyl)-3,4-dihydro-3-methyl- (9CI)
MF C13 H16 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 7-chloro-6-(3-chloropropyl)-3,4-dihydro-4,4-dimethyl- (9CI)
MF C14 H17 Cl2 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-benzo[b]thien-3-yl-, monohydrochloride (9CI)
MF C12 H14 N2 S . Cl H



● HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisothiazole, 7-fluoro-3-(1-piperazinyl)- (9CI)
MF C11 H12 F N3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C25 H30 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C25 H29 F N4 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(2-chloroethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C14 H18 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI)
MF C23 H27 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(2-chloroethyl)-3,4-dimethyl- (9CI)
MF C13 H14 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4-dimethyl-, hydrochloride (10:11) (9CI)
MF C24 H28 N4 O2 . 11/10 Cl H



●11/10 HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(2-chloroethyl)-3,4-dihydro-4-methyl-, (4S)- (9CI)
MF C12 H14 Cl N O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(2-chloroethyl)-3,4-dihydro-3-methyl- (9CI)
MF C12 H14 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisoxazole, 5-chloro-3-(1-piperazinyl)- (9CI)
MF C11 H12 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-4-methyl-, (4S)- (9CI)
MF C10 H11 N O

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzene, 1-(2-chloroethyl)-4-nitro- (6CI, 7CI, 8CI, 9CI)
MF C8 H8 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 1,2,3,4-tetrahydro- (8CI, 9CI)
MF C9 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propenoic acid, ethyl ester (9CI)
MF C5 H8 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4H-Cyclopenta[c]quinolin-4-one, 1,2,3,5-tetrahydro-8-hydroxy- (9CI)
MF C12 H11 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzenamine, 4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (9CI)
MF C19 H22 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro-6-methyl- (9CI)
MF C25 H26 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI)
MF C24 H25 F N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-pentyl- (9CI)
MF C30 H40 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-2-oxo- (9CI)
MF C26 H29 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-4-methyl- (9CI)
MF C29 H36 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo-, ethyl ester (9CI)
MF C27 H32 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-2-oxo- (9CI)
MF C26 H31 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-4-methyl-, monohydrochloride, (4S)- (9CI)
MF C24 H26 F N3 O S . Cl H

Absolute stereochemistry.



● HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H,5H-Benzo[ij]quinolizin-5-one, 9-(2-chloroethyl)-2,3,6,7-tetrahydro- (9CI)
MF C14 H16 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI)
MF C24 H26 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 8-chloro-6-(3-chloropropyl)-3,4-dihydro-4,4-dimethyl- (9CI)
MF C14 H17 Cl2 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 6-(3-chloropropyl)-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI)
MF C14 H20 Cl N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-4,4-dimethyl- (9CI)
MF C25 H29 F N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3-methyl- (9CI)
MF C24 H28 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-chloro-3,4-dihydro-4,4-dimethyl- (9CI)
MF C25 H29 Cl N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 1-(2-ethoxyethyl)-6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride (9CI)
MF C29 H37 F N4 O2 S . Cl H



● HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(5-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C25 H29 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 8-chloro-6-(2-chloroethyl)-3,4-dihydro-4,4-dimethyl- (9CI)
MF C13 H15 Cl2 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(chloroacetyl)-7-fluoro-3,4-dihydro-4,4,8-trimethyl- (9CI)

MF C14 H15 Cl F N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C25 H30 N4 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-3,3,4-trimethyl- (9CI)
MF C12 H15 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-, monohydrochloride (9CI)
MF C24 H26 N4 O2 . Cl H



● HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (4S)- (9CI)
MF C23 H26 N4 O2

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI)
MF C24 H28 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(3-chloro-1-oxopropyl)-3,4-dihydro-4-methyl- (9CI)
MF C13 H14 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-3,3-dimethyl- (9CI)
MF C11 H13 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 3,4-dihydro-4,4-dimethyl- (9CI)
MF C11 H13 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 1,2,3,4-tetrahydro-1-(3-methyl-1-oxo-2-butenyl)- (9CI)
MF C14 H17 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzene, (2-chloroethyl)- (7CI, 8CI, 9CI)
MF C8 H9 Cl
CI COM

$ClCH_2-CH_2-Ph$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Propane, 1,3-dibromo- (8CI, 9CI)
MF C3 H6 Br2
CI COM

$Br-CH_2-CH_2-CH_2-Br$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4H-Cyclopenta[c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-1,2,3,5-tetrahydro- (9CI)
MF C26 H28 N4 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro- (9CI)
MF C24 H24 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dimethyl- (9CI)
MF C25 H26 F N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-cyclobutyl-3,4-dihydro-4,4,8-trimethyl- (9CI)
MF C29 H36 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)- (9CI)
MF C26 H27 F3 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)- (9CI)
MF C26 H27 F3 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-

piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo-N-phenyl- (9CI)
MF C32 H35 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI)
MF C26 H31 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo- (9CI)
MF C26 H29 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-4-methyl-, (4S)- (9CI)
MF C24 H26 F N3 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H,5H-Benzo[ij]quinolizin-5-one, 9-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-2,3,6,7-tetrahydro- (9CI)
MF C25 H28 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI)
MF C27 H34 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-8-chloro-3,4-dihydro-4,4-dimethyl- (9CI)
MF C25 H29 Cl N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 1-acetyl-6-(3-chloropropyl)-7-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI)
MF C16 H21 Cl F N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4R)- (9CI)
MF C24 H28 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3,3-dimethyl- (9CI)
MF C25 H30 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-(3-chloropropyl)-3,4-dihydro-4,4-dimethyl- (9CI)
MF C14 H18 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(1-methylethyl)-, monohydrochloride (9CI)
MF C28 H35 F N4 O S . Cl H



L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzisoxazole, 5-fluoro-3-(1-piperazinyl)- (9CI)

MF C11 H12 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 8-chloro-3,4-dihydro-4,4-dimethyl- (9CI)
MF C11 H12 Cl N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride (9CI)
MF C25 H29 F N4 O S . Cl H



● HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl-, monohydrochloride (9CI)

MF C27 H34 N4 O S . Cl H



● HCl

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3,4-trimethyl- (9CI)
MF C25 H30 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI)
MF C23 H26 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Indole, 2,3-dihydro-1-(3-methyl-1-oxo-2-butenyl)- (9CI)
MF C13 H15 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L14 350 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI)
MF C23 H26 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d scan help

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.

L15 1 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN **Piperazine (8CI, 9CI)**
MF C4 H10 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    8.90     627.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -38.69

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:19:58 ON 18 SEP 2005
```